Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominick J Angiolillo

Showing results (601-610 of 764) with videos related to

Pageof 77
Sort By:
Journal of the American College of Cardiology|June 25, 2011
Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery diseaseDominick J Angiolillo, Esther Bernardo, Martina Zanoni, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|December 30, 2020
Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol ExperienceRoberta Rossini, Giulia Masiero, Claudia Fruttero, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 25, 2023
Ticagrelor enhances the cardioprotective effects of ischemic preconditioning in stable patients undergoing percutaneous coronary intervention: the TAPER-S randomized studyDomenico D'Amario, Mattia Galli, Attilio Restivo, et al.
Circulation|February 8, 2021
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 UpdateDominick J Angiolillo, Deepak L Bhatt, Christopher P Cannon, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 30, 2022
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapyMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
Circulation|February 16, 2026
Clopidogrel Versus Aspirin Monotherapy in Coronary Artery Disease: A Sex-Stratified Individual Patient Data Meta-Analysis of Randomized TrialsFelice Gragnano, Daniele Giacoppo, Ki Hong Choi, et al.
Thrombosis and Haemostasis|August 31, 2019
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT StudyFrancesco Franchi, Fabiana Rollini, Emilio Garcia, et al.
Circulation|December 7, 2007
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trialStephen D Wiviott, Dietmar Trenk, Andrew L Frelinger, et al.
JACC. Cardiovascular Interventions|February 11, 2026
Genotype-Guided vs Conventional Oral P2Y<sub>12</sub> Inhibitors in Acute Coronary Syndrome: A Combined Analysis of TAILOR-PCI and POPular GeneticsMattia Galli, Naveen L Pereira, Ryan J Lennon, et al.
Thrombosis and Haemostasis|January 4, 2022
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic DiseaseMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
Pageof 77

Showing results (601-610 of 764) with videos related to

Sort By:
Pageof 77
Journal of the American College of Cardiology|June 25, 2011
Impact of insulin receptor substrate-1 genotypes on platelet reactivity and cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery diseaseDominick J Angiolillo, Esther Bernardo, Martina Zanoni, et al.
TH Open : Companion Journal to Thrombosis and Haemostasis|December 30, 2020
Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol ExperienceRoberta Rossini, Giulia Masiero, Claudia Fruttero, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|November 25, 2023
Ticagrelor enhances the cardioprotective effects of ischemic preconditioning in stable patients undergoing percutaneous coronary intervention: the TAPER-S randomized studyDomenico D'Amario, Mattia Galli, Attilio Restivo, et al.
Circulation|February 8, 2021
Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective: 2021 UpdateDominick J Angiolillo, Deepak L Bhatt, Christopher P Cannon, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|March 30, 2022
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapyMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
Circulation|February 16, 2026
Clopidogrel Versus Aspirin Monotherapy in Coronary Artery Disease: A Sex-Stratified Individual Patient Data Meta-Analysis of Randomized TrialsFelice Gragnano, Daniele Giacoppo, Ki Hong Choi, et al.
Thrombosis and Haemostasis|August 31, 2019
Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT StudyFrancesco Franchi, Fabiana Rollini, Emilio Garcia, et al.
Circulation|December 7, 2007
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trialStephen D Wiviott, Dietmar Trenk, Andrew L Frelinger, et al.
JACC. Cardiovascular Interventions|February 11, 2026
Genotype-Guided vs Conventional Oral P2Y<sub>12</sub> Inhibitors in Acute Coronary Syndrome: A Combined Analysis of TAILOR-PCI and POPular GeneticsMattia Galli, Naveen L Pereira, Ryan J Lennon, et al.
Thrombosis and Haemostasis|January 4, 2022
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic DiseaseMattia Galli, Francesco Franchi, Fabiana Rollini, et al.
Pageof 77